Asterias Biotherapeutics, Inc. - FORM 10-K - EX-32 - EXHIBIT 32 - March 10, 2015

Attached files

file filename
EX-31 - EXHIBIT 31 - Asterias Biotherapeutics, Inc.ex31.htm
EX-23.1 - EXHIBIT 23.1 - Asterias Biotherapeutics, Inc.ex23_1.htm
EX-23.2 - EXHIBIT 23.2 - Asterias Biotherapeutics, Inc.ex23_2.htm
EX-10.26 - EXHIBIT 10.26 - Asterias Biotherapeutics, Inc.ex10_26.htm
EX-10.25 - EXHIBIT 10.25 - Asterias Biotherapeutics, Inc.ex10_25.htm
EX-10.27 - EXHIBIT 10.27 - Asterias Biotherapeutics, Inc.ex10_27.htm
EXCEL - IDEA: XBRL DOCUMENT - Asterias Biotherapeutics, Inc.Financial_Report.xls
10-K - ASTERIAS BIOTHERAPEUTICS, INC 10-K 12-31-2014 - Asterias Biotherapeutics, Inc.form10k.htm
Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Asterias Biotherapeutics, Inc. (the “Company”) for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we Pedro Lichtinger, Chief Executive Officer, and Robert W. Peabody, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 10, 2015

 
/s/ Pedro Lichtinger
  
 
Pedro Lichtinger
  
 
Principal Executive Officer
  
     
 
/s/ Robert W. Peabody
  
 
Robert W. Peabody
  
 
Principal Financial Officer
  
 
 

Asterias Biotherapeutics, Inc. Reports

Also read